Accidents vasculaires cérébraux
Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 10, Octobre 2009
Accidents vasculaires cérébraux
Page(s) 847 - 854
Section M/S revues : Accidents vasculaires cérébraux (2)
DOI https://doi.org/10.1051/medsci/20092510847
Publié en ligne 15 octobre 2009
  1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371 : 1612–32.
  2. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359 : 1317–29.
  3. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008; 55 : 363–89.
  4. Del Zoppo GJ. Inflammation and neurovascular unit in the setting of focal cerebral ischemia. Neuroscience 2009; 158 : 972–82.
  5. Shpargel KB, Jalabi W, Jin Y, et al. Preconditioning paradigms and pathways in the brain. Cleve Clin J Med 2008; 75 : S77–82.
  6. Hess DC, Borlongan CV. Cell-based therapy in ischemic stroke. Expert Rev Neurother 2008; 8 : 1193–201.
  7. Endres M, Engelhardt B, Koistinaho J, et al. Improving outcome after stroke : overcoming the translational roadblock. Cerebrovasc Dis 2008; 25 : 268–78.
  8. Obrenovitch TP. Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol Rev 2008; 88 : 211–47.
  9. Stenzel-Poore MP, Stevens SL, King JS, Simon RP. Preconditioning reprograms to response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes : a speculative synthesis. Stroke 2007; 38 (suppl 2) : 680–5.
  10. Bastide M, Ouk T, Plaisier F, et al. Neurogliovascular unit after cerebral ischemia: is the vascular wall a pharmacological target. Psychoneuroendocrinology 2007; 32 : S36–9.
  11. Goldstein LB. Statins and ischemic stroke severity: cytoprotection. Curr Atheroscler Rep 2009; 11 : 296–300.
  12. Bordet R, Ouk T, Petrault O, et al. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 2006; 34 : 1341–6.
  13. Blondeau N, Widmann C, Lazdunski M, Heurtaux C. Polyunsaturated fatty acids induce ischemic and epileptic tolerance. Neuroscience 2002; 109 : 231–41.
  14. Deplanque D, Masse I, Lefebvre C, et al. Prior TIA, lipid-lowering drug use, and physical activity decrease ischemic stroke severity. Neurology 2006; 67 : 1403–10.
  15. Zaleska MM, Mercado ML, Chavez J, et al. The development of stroke therapeutics: promising mechanisms and translational challenges. Neuropharmacology 2009; 56 : 329–41.
  16. Bordet R, Lestage P, Onteniente B. The concept of neuroprotective agents as a treatment modulators in the development of brain diseases. Therapie 2007; 62 : 463–72.
  17. Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009; 40 : 2244–50.
  18. Feuerstein GZ, Zaleska MM, Krams M, et al. Missing steps in the STAIR case : a translational medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab 2008; 28 : 217–9.
  19. Benchenane K, Castel H, Boulouard M, et al. Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory. J Cell Sci 2007; 120 : 578–85.
  20. Heurtaux C, Laigle C, Blondeau N, et al. Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. Neuroscience 2006; 137 : 241–51.
  21. Haddad M, Rhinn H, Bloquel C, et al. Anti-inflammatory effects of PJ34, a poly (ADP-ribose) polymerase inhibitor, in transcient focal cerebral ischemial in mice. Br J Pharmacol 2006; 149 : 23–30.
  22. Chauvier D, Ankri S, Charriaut-Marlangue C, et al. Broad-spectrum caspase inhibitors : from myth to reality ? Cell Death Differ 2007; 14 : 387–91.
  23. Onténiente B. Natural and synthetic inhibitors of caspases : targets for novel drugs. Curr Drug Targets CNS Neurol Disord 2004; 3 : 333–40.
  24. Guégan C, Braudeau J, Couriaud C, et al. PTD-XIAP protects against cerebral ischemia by anti-apoptotic and transcriptional regulatory mechanisms. Neurobiol Dis 2006; 22 : 177–86.
  25. Spahn A, Blondeau N, Heurteaux C, et al. Concomitant transitory up-regulation of X-linked inhibitor of apoptosis protein (XIAP) and the heterogeneous nuclear ribonucleoprotein C1-C2 in surviving cells during neuronal apoptosis. Neurochem Res 2008; 33 : 1859–68.
  26. Lok J, Gupta P, Guo S, et al. Cell-cell signalling in neurovascular unit. Neurochem Res 2007; 32 : 2032–45
  27. Villapol S, Gelot A, Renolleau S, Charriaut-Marlangue C. Astrocyte responses after neonatal ischemia : the yin and the yang. Neuroscientist 2008; 14 : 339–44.
  28. Amantea D, Nappi G, Bernardi G, et al. Post-ischemic brain damage : pathophysiology and role of inflammatory mediators. FEBS J 2009; 276 : 13–26.
  29. Fisher M. Injuries to the vascular endothelium: vascular wall and endothelial dysfunction. Rev Neurol Dis 2008; 5 : S4–11.
  30. Gautier S, Ouk T, Petrault O, et al. Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemia. Br J Pharmacol 2009; 156 : 673–9.
  31. Zhao BQ, Tejima E, Lo EH. Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke 2007; 38 (suppl 2) : 748–52.
  32. Minnerup J, Schäbitz WR. Multifunctional actions of approved and candidate stroke drugs. Neurotherapeutics 2009; 6 : 43–52.
  33. Rodriguez-Gonzalez R, Hurtado O, Sobrino T, Castillo J. Neuroplasticity and cellular therapy in cerebral infarction. Cerebrovasc Dis 2007; 24 : S167–80.
  34. Tardy J, Pariente J, Leger A, et al. Methylphenidate modulates cerebral post-stroke reorganization. Neuroimage 2006; 33 : 913–22.
  35. Bacigaluppi M, Pluchino S, Martino G, et al. Neural stem/precursor cells for the treatment of ischemic stroke. J Neurol Sci 2008; 265 : 73–7.
  36. Vivien D, Gauberti M, Guedin P, Anglés-Cano E. Comment optimiser l’utilisation du tPA ? Med Sci (Paris) 2009; 25 : 855–7.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.